IL241587B - Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof - Google Patents

Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Info

Publication number
IL241587B
IL241587B IL241587A IL24158715A IL241587B IL 241587 B IL241587 B IL 241587B IL 241587 A IL241587 A IL 241587A IL 24158715 A IL24158715 A IL 24158715A IL 241587 B IL241587 B IL 241587B
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical composition
ampk activator
serotonergic agent
serotonergic
Prior art date
Application number
IL241587A
Other languages
English (en)
Hebrew (he)
Inventor
Chen Chien-Hung
Original Assignee
Als Mountain Llc
Chien Hung Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL241587(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Als Mountain Llc, Chien Hung Chen filed Critical Als Mountain Llc
Publication of IL241587B publication Critical patent/IL241587B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
IL241587A 2013-03-15 2015-09-16 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof IL241587B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793407P 2013-03-15 2013-03-15
PCT/US2014/028413 WO2014144130A2 (en) 2013-03-15 2014-03-14 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Publications (1)

Publication Number Publication Date
IL241587B true IL241587B (en) 2019-01-31

Family

ID=51538303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241587A IL241587B (en) 2013-03-15 2015-09-16 Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof

Country Status (16)

Country Link
US (1) US20140350064A1 (enExample)
EP (1) EP2983473A4 (enExample)
JP (1) JP2016513734A (enExample)
KR (1) KR20160005341A (enExample)
CN (1) CN105636438A (enExample)
AR (1) AR095631A1 (enExample)
AU (1) AU2014227807B2 (enExample)
BR (1) BR112015023922A2 (enExample)
CA (1) CA2909633A1 (enExample)
CL (1) CL2015002680A1 (enExample)
HK (1) HK1222297A1 (enExample)
IL (1) IL241587B (enExample)
MX (1) MX2015012760A (enExample)
RU (1) RU2015143438A (enExample)
TW (1) TW201444552A (enExample)
WO (1) WO2014144130A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180071269A1 (en) * 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
ES2567105B1 (es) * 2014-09-19 2017-02-10 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
WO2017018752A1 (ko) * 2015-07-29 2017-02-02 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
WO2017023833A1 (en) 2015-08-01 2017-02-09 Petti Stephen J Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
CN105541665A (zh) * 2016-02-18 2016-05-04 江苏大学 一种抗肿瘤药物化合物及制备方法和应用
KR101838622B1 (ko) * 2016-09-20 2018-03-14 김브라이언 아디포넥틴 수용체에 대한 작용제 펩타이드
AU2017340403B2 (en) * 2016-10-05 2022-03-17 The United States as Represented by the Department of Veterans Affairs Small molecule AMPK activators
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN107252425A (zh) * 2017-07-12 2017-10-17 上海华堇生物技术有限责任公司 去氢延胡索素的药物用途
EP3713568A1 (en) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CN108159044A (zh) * 2018-02-26 2018-06-15 华中科技大学 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN111892516A (zh) * 2018-08-08 2020-11-06 中国人民解放军总医院 抗肿瘤化合物
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109771424B (zh) * 2019-03-11 2021-03-16 马慧 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
CN110559298A (zh) * 2019-10-28 2019-12-13 中国药科大学 一种天然化合物Egenine用于制备抗肾纤维化药物的用途
AU2020372682A1 (en) * 2019-10-31 2022-06-09 Jd Bioscience Inc. Tricyclic compound and pharmaceutical use thereof
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
EP4366731A4 (en) 2021-07-07 2025-04-16 Terran Biosciences, Inc. N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF
CA3237988A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
KR20250164150A (ko) * 2022-12-05 2025-11-24 엔베다 테라퓨틱스, 인크. 장 또는 복통 치료를 위한 누트카톤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US20070244202A1 (en) * 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
DK2118279T3 (en) * 2007-01-16 2018-02-26 Ipintl Llc HIS UNKNOWN COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
US20120232003A1 (en) * 2009-03-13 2012-09-13 Takahashi Joseph S Compositions and methods for diabetes treatment
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition

Also Published As

Publication number Publication date
CA2909633A1 (en) 2014-09-18
HK1222297A1 (zh) 2017-06-30
EP2983473A2 (en) 2016-02-17
AR095631A1 (es) 2015-10-28
AU2014227807B2 (en) 2018-03-08
JP2016513734A (ja) 2016-05-16
MX2015012760A (es) 2016-06-17
RU2015143438A (ru) 2017-04-21
CN105636438A (zh) 2016-06-01
AU2014227807A1 (en) 2015-11-05
WO2014144130A3 (en) 2015-02-05
EP2983473A4 (en) 2016-11-23
US20140350064A1 (en) 2014-11-27
TW201444552A (zh) 2014-12-01
WO2014144130A2 (en) 2014-09-18
KR20160005341A (ko) 2016-01-14
CL2015002680A1 (es) 2016-09-02
BR112015023922A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
EP2983473A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONINERGIC AGENT AND METHODS OF USING SAME
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
TWI560180B (en) Substituted benzamides and methods of use thereof
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
ZA201602948B (en) Compositions comprising a defined microbiome and methods of use thereof
ZA201601701B (en) Inhibitors of erk and methods of use
SI3932932T1 (sl) Nevroaktivni steroidi in postopki za uporabo le-teh
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2973253A4 (en) Integrated modular health platforms and methods of use
IL240729A0 (en) Solid compounds containing glucodinase activator, methods for their preparation, and their use
IL244066A0 (en) Triazolopyridine compounds, preparations and methods for their use
HUE067221T2 (hu) IL-1béta inhibitor készítmény és annak alkalmazása
EP3049389A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL244901A0 (en) Derivatives of aminotetralin and aminoindan, pharmaceutical compositions containing them and their use in therapy
EP3074028A4 (en) Activity enhancing curcumin compositions and methods of use
IL240505A0 (en) Accumulations of lanthanides and methods for their use
EP3049077A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB201301979D0 (en) New composition and use thereof
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
PL3024825T3 (pl) Imidazolokarboksyamidy i ich zastosowanie jako inhibitorów faah
GB201518035D0 (en) Prebiotic composition and method of its use
GB201518882D0 (en) Agrochemical composition and method of use thereof
IL239872A0 (en) Metriptase inhibitors and pharmaceutical preparations containing them
TH1501005528A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วย ampk แอกติเวเตอร์ และซีโรโทเนอร์จิกเอเจนต์ และวิธีการใช้ของสิ่งนี้
GB201310349D0 (en) Composition and method of use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees